This post-hoc analysis of PREVAIL evaluated the proportion of patients with ≥50% or ≥75% reduction in monthly headache days (MHDs; based on Migraine Disability Assessment [MIDAS]) at Weeks 12 or 24 who sustained that reduction through subsequent 12-week dosing intervals up to Week 84.

The phase 3 PREVAIL single-arm, open-label, long-term safety study showed a favorable safety profile consistent with previous trials and reductions in migraine burden over 2 years in patients treated with eptinezumab.

PREVAIL was a single-arm, open-label trial evaluating long-term outcomes of eptinezumab treatment in adults aged 18-65 years with chronic migraine. Patients received eptinezumab 300 mg intravenously every 12 weeks. This post-hoc analysis evaluated the proportion of patients with ≥50% or ≥75% reduction in MHDs, based on the reduction in MIDAS-derived headache frequency after the first or second dosing intervals (Weeks 12 or 24, respectively), who sustained that reduction through the remaining 12-week dosing intervals up to Week 84.

More than half of patients with ≥50% or ≥75% reduction in MHDs after the first or second dose experienced sustained reductions in headache frequency with continued eptinezumab treatment, indicating that early response may predict sustained response.